<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Ginkgo biloba extract (EGb) and <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi> (LA) are commercially available "<z:chebi fb="11" ids="22586">antioxidant</z:chebi> supplements" with a variety of actions that may be beneficial during <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>These actions include inhibiting platelet and leukocyte activation and <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, reducing free radical generation, and increasing cerebral blood flow </plain></SENT>
<SENT sid="2" pm="."><plain>Both EGb and LA have been shown to be neuroprotective in cell culture and global central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> models </plain></SENT>
<SENT sid="3" pm="."><plain>In this study we investigated the neuroprotective efficacy of EGb and LA in a clinically relevant, transient focal central <z:mp ids='MP_0008912'>nervous</z:mp> system ischemic model </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: In the EGb study, 60 adult C57blk mice were randomized to treatment with EGb given orally (via gavage) for 7 days: low dose, 50 EGb mg/kg daily; high dose, 100 mg/kg daily; matched placebo </plain></SENT>
<SENT sid="5" pm="."><plain>On day 7, reversible middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> was produced by advancing a <z:chebi fb="144" ids="48140">silicone</z:chebi>-coated 8-0 filament into the internal carotid artery for 45 minutes followed by reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>At 24 hours, the animals were evaluated on a 28-point clinical scale, and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was determined with the use of triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>In the LA study, 24 C57blk mice were treated with 100 mg/kg SC of LA or placebo 1.5 hours before transient MCAO, as in the EGb study </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In the EGb study, values for <z:mpath ids='MPATH_124'>infarct</z:mpath> volume at 24 hours were as follows (mean+/-SD): low dose (n=18), 13+/-5 mm(3); high dose (n=22), 22+/-12 mm(3); placebo (n=20), 20+/-10 mm(3) (P:=0.03 overall; P=0.02, low dose versus placebo) </plain></SENT>
<SENT sid="9" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> percentage of hemisphere values were as follows: low dose, 14+/-5%; high dose, 21+/-11%; placebo, 20+/-9% (P=0.03 overall; P=0.02, low dose versus placebo) </plain></SENT>
<SENT sid="10" pm="."><plain>Ten percent of the high-dose group showed significant <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>) within the <z:mpath ids='MPATH_124'>infarct</z:mpath>, while no <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> was seen in the other groups </plain></SENT>
<SENT sid="11" pm="."><plain>Neurological function scores were as follows: low dose, 11.8+/-1.5; high dose, 11.4+/-1.7; placebo, 11.3+/-1.8 (P=NS) </plain></SENT>
<SENT sid="12" pm="."><plain>In the LA study, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was as follows: 100 mg/kg LA (n=12), 16.8+/-8.3 mm(3); placebo (n=12), 27.2+/-14.6 mm(3) (P&lt;0.05) </plain></SENT>
<SENT sid="13" pm="."><plain>LA also produced a significant improvement in neurological function at 24 hours: LA, 9.5+/-1.2; placebo, 11.2+/-1.8 (P=0.02) </plain></SENT>
<SENT sid="14" pm="."><plain>There was no evidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> in any of the animals </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: Both oral EGb and LA therapies produced significant reductions in <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="16" pm="."><plain>However, for EGb this beneficial effect appears to be dose related, with higher doses potentially increasing the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> </plain></SENT>
</text></document>